<DOC>
	<DOCNO>NCT01420458</DOCNO>
	<brief_summary>This open-label , single-center , 2 period crossover , PK profile study . Each subject randomize 1 2 treatment sequence . Both treatment sequence enrol concurrently .</brief_summary>
	<brief_title>Study Healthy Volunteers Establish BioEquivalence Two Formulations BG00012</brief_title>
	<detailed_description>This study healthy volunteer demonstrate bioequivalence two formulation BG-00012 give capsule form..</detailed_description>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Must give write informed consent authorization require local law . Males females 18 55 year old inclusive time consent . Must body mass index ( BMI ) 19 kg/m2 30 kg/m2 , inclusive History malignancy ( subject basal cell carcinoma completely excise prior study entry remain eligible ) . Known history positive test result Human Immunodeficiency Virus ( HIV ) History severe allergic anaphylactic reaction . History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric renal major disease , determine Investigator . Clinically significant abnormal hematology blood chemistry value , determine Investigator , screen value alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) total bilirubin , creatinine upper limit normal , normal range screen value white blood cell ( WBC ) . Current enrollment drug , biologic , device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>bioequivalence</keyword>
</DOC>